tesamorelin



tesamorelin

Y1YY1A2AA2D3DD3A4AA4I5II5F6FF6T7TT7N8NN8S9SS9Y10YY10R11RR11K12KK12V13VV13L14LL14G15GG15Q16QQ16L17LL17S18SS18A19AA19R20RR20K21KK21L22LL22L23LL23Q24QQ24D25DD25I26II26M27MM27S28SS28R29RR29Q30QQ30Q31QQ31G32GG32E33EE33S34SS34N35NN35Q36QQ36E37EE37R38RR38G39GG39A40AA40R41RR41A42AA42R43RR43L44LL44

SMILES None
InChIKey QBEPNUQJQWDYKU-BMGKTWPMSA-N
Sequence YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)


No bioactivity data available.

tesamorelin

Y1YY1A2AA2D3DD3A4AA4I5II5F6FF6T7TT7N8NN8S9SS9Y10YY10R11RR11K12KK12V13VV13L14LL14G15GG15Q16QQ16L17LL17S18SS18A19AA19R20RR20K21KK21L22LL22L23LL23Q24QQ24D25DD25I26II26M27MM27S28SS28R29RR29Q30QQ30Q31QQ31G32GG32E33EE33S34SS34N35NN35Q36QQ36E37EE37R38RR38G39GG39A40AA40R41RR41A42AA42R43RR43L44LL44

Drug properties

Molecular type Peptide
Physiological/Surrogate Surrogate
Approved drug Yes

Distribution across phases (no. indications)

Phase I 0
Phase II 6
Phase III 0
Phase IV 2


Sankey plot


Drug Information